当诺和诺德的司美格鲁肽依旧在减肥药市场横扫天下之时,又一国产 创新药 加入了对司美格鲁肽“药王”地位的挑战。近日,由北京大学人民医院纪立农教授团队牵头开展的全球首个申报上市的偏向型GLP-1受体激动剂——埃诺格鲁肽(Ecnoglutide,曾用名伊诺格鲁肽)注射液,其中国超重或肥胖受试者Ⅲ期临床试验(SLIMMER)研究成果在第85届美国糖尿病协会(ADA)学术会议上以口头报告发布,该研究全文同步...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.